Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1992 4
1993 23
1994 1
1995 2
1997 2
1998 1
2006 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs.
Mizojiri K, Futaguchi S, Norikura R, Katsuyama Y, Nagasaki T, Yoshimori T, Nakanishi M. Mizojiri K, et al. Antimicrob Agents Chemother. 1995 Jul;39(7):1445-53. doi: 10.1128/AAC.39.7.1445. Antimicrob Agents Chemother. 1995. PMID: 7492083 Free PMC article.
[pivaloyl-14C]S-1108, which is 14C labeled at the pivalic acid moiety of the pivaloyloxymethyl side chain of S-1108, was administered orally to rats and dogs, and the disposition of pivalic acid cleft from S-1108 was examined. ...The diff …
[pivaloyl-14C]S-1108, which is 14C labeled at the pivalic acid moiety of the pivaloyloxymethyl side chain of S-1108 …
[Pharmacokinetic and clinical studies of S-1108 in the pediatric field. Pediatric Study Group of S-1108].
Fujii R, Abe T, Tajima T, Terashima I, Meguro H, Mori A, Sato H, Niino K, Sunakawa K, Yokota T, et al. Fujii R, et al. Jpn J Antibiot. 1995 Jul;48(7):921-41. Jpn J Antibiot. 1995. PMID: 7563586 Clinical Trial. Japanese.
S-1108 in granules, a new oral cephem antibiotic, was pharmacokinetically and clinically evaluated in the pediatric field and the following results were obtained. 1. ...Urinary recovery rates were 12.5-30.0% in the first 8(6) hours after administration. 2. Clinical …
S-1108 in granules, a new oral cephem antibiotic, was pharmacokinetically and clinically evaluated in the pediatric field and …
Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores.
Nakashima M, Uematsu T, Oguma T, Yoshida T, Mizojiri K, Matsuno S, Yamamoto S. Nakashima M, et al. Antimicrob Agents Chemother. 1992 Apr;36(4):762-8. doi: 10.1128/AAC.36.4.762. Antimicrob Agents Chemother. 1992. PMID: 1503438 Free PMC article. Clinical Trial.
S-1108, the prodrug of S-1006, was given to healthy volunteers three times a day (TID) for 8 days in a dose of 200 mg in a crossover placebo-controlled study. The safety of S-1108 and the pharmacokinetics of S-1006 and pivalic acid liberated from pival …
S-1108, the prodrug of S-1006, was given to healthy volunteers three times a day (TID) for 8 days in a dose of 200 mg in a cro …
Carnitine status and safety after administration of S-1108, a new oral cephem, to patients.
Shimizu K, Saito A, Shimada J, Ohmichi M, Hiraga Y, Inamatsu T, Shimada K, Tanimura M, Fujita Y, Nishikawa T, et al. Shimizu K, et al. Antimicrob Agents Chemother. 1993 May;37(5):1043-9. doi: 10.1128/AAC.37.5.1043. Antimicrob Agents Chemother. 1993. PMID: 8517691 Free PMC article.
The metabolism and clinical safety of the pivalic acid-containing antibiotic S-1108, an orally active pro-drug cephalosporin, were investigated to assess the clinical effects, with special emphasis on the influence of carnitine consumption in 15 patients with variou …
The metabolism and clinical safety of the pivalic acid-containing antibiotic S-1108, an orally active pro-drug cephalosporin, …
Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans.
Totsuka K, Shimizu K, Konishi M, Yamamoto S. Totsuka K, et al. Antimicrob Agents Chemother. 1992 Apr;36(4):757-61. doi: 10.1128/AAC.36.4.757. Antimicrob Agents Chemother. 1992. PMID: 1503437 Free PMC article.
The metabolism and pharmacokinetics of pivalic acid, a major metabolite of S-1108, were studied with three healthy volunteers. Concentrations of S-1006 (the active compound), pivalic acid, and pivaloylcarnitine in plasma and urine were measured after administration …
The metabolism and pharmacokinetics of pivalic acid, a major metabolite of S-1108, were studied with three healthy volunteers. …
In vitro activity and susceptibility to hydrolysis of S-1006.
Neu HC, Gu JW, Fang W, Chin NX. Neu HC, et al. Antimicrob Agents Chemother. 1992 Jun;36(6):1336-41. doi: 10.1128/AAC.36.6.1336. Antimicrob Agents Chemother. 1992. PMID: 1416835 Free PMC article.
The in vitro activity of S-1006, the active component of a new orally absorbed cephalosporin, S-1108, inhibited 90% of Staphylococcus aureus isolates at less than or equal to 2 micrograms/ml, 90% of group A, B, C, F, and G streptococci and Streptococcus pneumoniae i …
The in vitro activity of S-1006, the active component of a new orally absorbed cephalosporin, S-1108, inhibited 90% of Staphyl …
[Pharmacokinetic, bacteriological and clinical studies on S-1108 in children].
Tajima T, Kondo Y, Negishi S, Nishimura S, Yoshida A, Hagiwara N, Niimi R, Esaki E, Kaneko S, Abe T. Tajima T, et al. Jpn J Antibiot. 1993 Nov;46(11):953-8. Jpn J Antibiot. 1993. PMID: 8309071 Japanese.
Pharmacokinetic, bacteriological and clinical studies on S-1108 were performed in children. The results were as follows: 1. A total of 11 patients were treated with S-1108. Each dose was 3 mg/kg, orally administered 3 times daily for 4-14 days. ...
Pharmacokinetic, bacteriological and clinical studies on S-1108 were performed in children. The results were as follows: 1. A …
[Pharmacokinetic and clinical studies of S-1108 in the pediatric field].
Toyonaga Y, Ishihara T, Tezuka T, Sano T, Nakamura H. Toyonaga Y, et al. Jpn J Antibiot. 1993 Nov;46(11):991-1002. Jpn J Antibiot. 1993. PMID: 8309075 Japanese.

Pharmacokinetic and clinical studies on S-1108, a new oral cephem antibiotic, were performed in the field pediatrics. ...MIC values ranged < or = 0.025-1.56 for GPC and < or = 0.025-0.78 microgram/ml for GNR. 2) Absorption and excretion Blood concentrations an

…
Pharmacokinetic and clinical studies on S-1108, a new oral cephem antibiotic, were performed in the field pediatrics. ...MIC v …
[Basic and clinical studies on S-1108 in pediatric field].
Motohiro T, Handa S, Yamada S, Oki S, Yoshinaga Y, Aramaki M, Oda K, Sakata Y, Kato H, Yamashita F, et al. Motohiro T, et al. Jpn J Antibiot. 1993 Dec;46(12):1122-44. Jpn J Antibiot. 1993. PMID: 8107277 Clinical Trial. Japanese.
S-1108 is a new oral esterified cephem antibiotic. Its active form, S-1006, has a broad antimicrobial spectrum against both Gram-positive and Gram-negative bacteria. ...In the present study, we conducted laboratory and clinical evaluations of S-1108 gr …
S-1108 is a new oral esterified cephem antibiotic. Its active form, S-1006, has a broad antimicrobial spectrum against both Gr …
35 results